WILMINGTON, N.C., Sept. 21, 2011 (GLOBE NEWSWIRE) — TranS1 Inc. (Nasdaq:TSON) today announced that it has priced its public offering of 6,200,000 shares of its common stock at a price to the public of $3.25 per share. TranS1 has granted the underwriters a 30-day option to purchase up to 930,000 additional shares of common stock to cover over-allotments, if any. The gross proceeds to TranS1 from the sale of shares, before expenses and any over-allotment exercise, are expected to be $20,150,000. The closing of the offering is expected to take place on September 26, 2011. Piper Jaffray & Co. is acting as the sole book-running manager for the offering and Canaccord Genuity is acting as co-manager.
A shelf registration statement relating to the shares of common stock was originally filed with the Securities and Exchange Commission on May 16, 2011, which became effective on August 1, 2011. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and related prospectus may be obtained, when available, by contacting Piper Jaffray & Co. at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402, or by telephone at (800) 747-3924.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.
About TranS1 Inc.
TranS1 is a medical device company focused on designing, developing and marketing products that implement its proprietary approach to treat degenerative conditions of the spine affecting the lower lumbar region. TranS1 currently markets the AxiaLIF family of products for single and two level lumbar fusion and the Vectre and Avatar posterior fixation systems for lumbar fixation supplemental to AxiaLIF fusion. TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit www.trans1.com.
Forward-Looking Statements
In addition to historical information, this release contains forward looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Actual results could differ materially from those projected in forward-looking statements as a result of the following factors, among others: the acceptance and continued use of our products by surgeons; the lack of clinical data about the efficacy of our products; uncertainty of reimbursement from third-party payors; our historical lack of profitability; competitive pressures from substitute products and larger companies and rapid technological change; our ability to build effective sales and marketing capabilities; regulatory approval and market acceptance for new products; our reliance on a limited number of suppliers to provide its products; cost pressures in the healthcare industry; and our ability to conduct successful clinical studies. Readers are urged to carefully review and consider the various disclosures made by us, which attempt to advise interested parties of the risks, uncertainties, and other factors that may affect our business, operating results and financial condition, and the value of our common stock and other securities, including without limitation the disclosures made under the caption “Risk Factors” in the prospectus supplement, the accompanying prospectus and in the documents we have incorporated by reference into the prospectus supplement and the accompanying prospectus, for a discussion of other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules of the NASDAQ Stock Market.
